Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27

Histopathology

Volumn 41, Issue 5, 2002, Pages 437-445

  An, H J ^a,c   Lee, Y H ^a   Cho, N H ^b   Shim, J Y ^a   Kim, J Y ^a   Lee, C ^a   Kim, S J ^a  

^a CHA University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Bundang CHA Hospital   (South Korea)

Author keywords

Endometrial carcinoma; Immunohistochemistry; p27; PTEN

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P27;

ARTICLE; CANCER INHIBITION; CELL CYCLE; DISEASE ASSOCIATION; DOWN REGULATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENZYME ACTIVITY; GENE MUTATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; TUMOR SUPPRESSOR GENE;

CARCINOMA, ENDOMETRIOID; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYSTADENOCARCINOMA, SEROUS; DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM PROTEINS; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEINS;

EID: 0036428714     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2002.01455.x     Document Type: Article

References (24)

1. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275; 1943-1947.
2. Steck PA, Pershouse MA, Jasser SA et al. Identification of a candidate tumor suppressor gene, MMAC1 at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 1997; 15; 356-362.
3. Risinger JI, Hayes AK, Berchuck A, Barett JC. PTEN / MMAC1 mutations in endometrial cancers. Cancer Res. 1997; 57; 4736-4738.
4. Tashiro H, Blazes MS, Wu R et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997; 57; 3935-3940.
5. Peiffer SL, Herzog TJ, Tribune DJ, Mutch DG, Gersell DJ, Goodfellow PJ. Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. Cancer Res. 1995; 55; 1922-1926.
6. Nagase S, Yamakaswa H, Sato S, Yajima A, Horii A. Identification of a 790-kilobase region of common allelic loss in chromosome 10q25-q26 in human endometrial cancer. Cancer Res. 1997; 57; 1630-1633.
7. Mutter GL, Lin MC, Fitzgerald JT et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J. Natl. Cancer Inst. 2000; 92; 924-931.
8. Podsypanina K, Ellenson LH, Nemes A et al. Mutation of Pten / Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. USA 1999; 96; 1563-1568.
9. cas. Cancer Res. 1999; 59; 4342-4349.
10. Sakudra A, Hamada H, Fukushige S et al. Adenovirus mediated delivery of the PTEN gene inhibits cell growth by induction of apoptosis in endometrial cancer. Int. J. Oncol. 1999; 15; 1069-1074.
11. KIP1 into cyclin E / CDK2 complexes. Cancer Res. 1999; 59; 2318-2323.
12. Li DM, Sun H. PTEN / MMAC1 / TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc. Natl. Acad. Sci. USA 1998; 95; 15406-15411.
13. Weng LP, Smith WM, Dahia PLM et al. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res. 1999; 59; 5808-5814.
14. Bockman JV. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 1983; 15; 10-17.
15. Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh. Dtch. Ges. Pathol. 1997; 81; 228-232.
16. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: Evidence for diverse pathways of tumorigenesis. Hum. Pathol. 1995; 26; 1268-1274.
17. Kong D, Suzuki A, Zou TT et al. PTEN is frequently mutated in primary endometrial carcinoma. Nat. Genet. 1997; 17; 143-144.
18. Bussaglia E, del Rio E, Matias-Guiu X, Prat J. PTEN mutations in endometrial carcinomas. A molecular and clinicopathologic analysis of 38 cases. Hum. Pathol. 2000; 31; 312-317.
19. Ali IU. Gatekeeper for endometrium: The PTEN tumor suppressor gene. J. Natl. Cancer Inst. 2000; 92; 861-863.
20. Maxwell GL, Risinger JI, Gumbs C et al. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res. 1998; 58; 2500-2503.
21. Levine RL, Cargile CB, Blazes MS, van Rees B, Kurman RJ, Ellenson LH. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion of uterine endometrioid carcinoma. Cancer Res. 1998; 58; 3254-3258.
22. Weng LP, Brown JL, Eng C. PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum. Mol. Genet. 2001; 15; 599-604.
23. Zhu X, Kwon CH, Schlosshauer PW, Ellenson LH, Baker SJ. PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells. Cancer Res. 2001; 61; 4569-4575.
24. Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am. J. Pathol. 2001; 158; 2097-2106.